News Focus
News Focus
Followers 843
Posts 122803
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 1463

Thursday, 10/25/2007 9:30:25 AM

Thursday, October 25, 2007 9:30:25 AM

Post# of 3757
3Q07 Baraclude sales: $72M, +227% vs 3Q06 and +22% vs 2Q07:

http://biz.yahoo.com/prnews/071025/nyth026.html?.v=101

>>
Sales of BARACLUDE®, an oral antiviral agent for the treatment of chronic hepatitis B, increased to $72 million in the third quarter of 2007 from $22 million in the same period in 2006, due to continued growth across all markets.

<<

It’s now up to a $288M annualized rate and is closing in on Hepsera for the top spot.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”